ArticleJournal of immunology (Baltimore, Md. : 1950)2016
Fluvastatin Suppresses Mast Cell and Basophil IgE Responses: Genotype-Dependent Effects.
Article in Journal of immunology (Baltimore, Md. : 1950), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Trial
- The HMG-CoA Reductase Inhibitor Fluvastatin Promotes Th2-Skewed Immune Responses by Modulating Dendritic Cell Differentiation.Genes to cells : devoted to molecular & cellular mechanisms · 2026Article
- Impaired cortical actin dynamics via lanosterol-dependent HMG-CoA reductase downregulation mediates IFN-α-induced mast cell stabilization.The Journal of biological chemistry · 2026Article
- Comorbidity Profile of Chronic Mast Cell-Mediated Angioedema Versus Chronic Spontaneous Urticaria.Biomedicines · 2025Article
- Molecular mechanisms underlying the effects of statins on bone metabolism: an evolving paradigm of statins delivery modalities for bone regeneration.Pharmacological reports : PR · 2025Review
- IL-33-mediated mast cell and eosinophil function requires isoprenylation.Frontiers in immunology · 2025Article
- Synovial mast cells and osteoarthritis: Current understandings and future perspectives.Heliyon · 2024Review
- Mast cell stabilizers: from pathogenic roles to targeting therapies.Frontiers in immunology · 2024Review
- Inhibiting Isoprenylation Suppresses FcεRI-Mediated Mast Cell Function and Allergic Inflammation.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- The effects of statins on the function and differentiation of blood cells.Archives of medical science : AMS · 2023Article
- Review
- Molecular targets of statins and their potential side effects: Not all the glitter is gold.European journal of pharmacology · 2022Review
- Hypersensitivity and in-stent restenosis in coronary stent materials.Frontiers in bioengineering and biotechnology · 2022Review
- Fluvastatin enhances IL-33-mediated mast cell IL-6 and TNF production.Cellular immunology · 2022Article
- Fluvastatin Induces Apoptosis in Primary and Transformed Mast Cells.The Journal of pharmacology and experimental therapeutics · 2020Article
- The Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review.Current atherosclerosis reports · 2020Review
- Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19.Frontiers in pharmacology · 2020Article
- Lactic acid suppresses IgE-mediated mast cell function in vitro and in vivo.Cellular immunology · 2019Article
- Polymer scaffold architecture is a key determinant in mast cell inflammatory and angiogenic responses.Journal of biomedical materials research. Part A · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
Abstract
Mast cell (MC)- and basophil-associated inflammatory diseases are a considerable burden to society. A significant portion of patients have symptoms despite standard-of-care therapy. Statins, used to lower serum cholesterol, have immune-modulating activities. We tested the in vitro and in vivo effects of statins on IgE-mediated MC and basophil activation. Fluvastatin showed the most significant inhibitory effects of the six statins tested, suppressing IgE-induced cytokine secretion among mouse MCs and basophils. The effects of fluvastatin were reversed by mevalonic acid or geranylgeranyl pyrophosphatase, and mimicked by geranylgeranyl transferase inhibition. Fluvastatin selectively suppressed key FcεRI signaling pathways, including Akt and ERK. Although MCs and basophils from the C57BL/6J mouse strain were responsive to fluvastatin, those from 129/SvImJ mice were completely resistant. Resistance correlated with fluvastatin-induced upregulation of the statin target HMG-CoA reductase. Human MC cultures from eight donors showed a wide range of fluvastatin responsiveness. These data demonstrate that fluvastatin is a potent suppressor of IgE-mediated MC activation, acting at least partly via blockade of geranyl lipid production downstream of HMG-CoA reductase. Importantly, consideration of statin use for treating MC-associated disease needs to incorporate genetic background effects, which can yield drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.